All In Biotech

Drug Trial Radar · NCT07691190

Bioequivalence Study to Compare Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) Versus Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine)

Single Dose Oral Bioequivalence Study of Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) and Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) in Healthy Adult Human Participants Under Fasting Conditions.

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Mar 5, 2026

Primary completion

Jun 2, 2026

Study completion Jun 26, 2026

Sponsor

Lead sponsor
Humanis Saglık Anonim SirketiIndustry
Sponsor type
Industry
First posted
Jul 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Single dose oral bioequivalence study of Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine hydrochloride) and Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) in healthy adult human participants under fasting conditions.

Conditions

  • SCHIZOPHRENIA 1 (Disorder)

Interventions

  • Cariprazine Hard CapsulesDrug

    1 capsule of 1.5 mg Cariprazine hydrochloride

  • Reagila® Hartkapseln (Hard Capsules) (Cariprazine)Drug

    1 capsule of 1.5 mg Cariprazine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The area under the plasma concentration versus time curve calculated using the linear trapezoidal rule from the zero time point to the 72 hours (AUC72)Time frame: 72.00 hours
  2. Maximum measured plasma concentration (Cmax)Time frame: 72.00 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliantha Research Limited

    Gujrāt, Vadodara, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.